EcoDrugPlus

Il2 Inducible T Cell Kinase

Ensembl ID : ENSPNAG00000020462
Gene Symbol: ITK
3 Cross references
207 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSPNAG00000008445
Gene Symbol: JAK1
3 Cross references
212 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSPNAG00000017528
Gene Symbol: JAK1
3 Cross references
165 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSPNAG00000017477
Gene Symbol: JAK2
3 Cross references
199 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSPNAG00000029911
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:

Map Kinase-Activated Protein Kinase 2

Ensembl ID : ENSPNAG00000001437
Gene Symbol: LOC108436487
3 Cross references
145 Possible Orthologues:

Map Kinase-Activated Protein Kinase 2-Like

Ensembl ID : ENSPNAG00000007372
Gene Symbol: LOC108414051
3 Cross references
173 Possible Orthologues:

Map Kinase-Interacting Serine/threonine-Protein Kinase 2-Like

Ensembl ID : ENSPNAG00000014554
Gene Symbol: LOC108439664
3 Cross references
208 Possible Orthologues:

Map Kinase-Interacting Serine/threonine-Protein Kinase 2-Like

Ensembl ID : ENSPNAG00000009782
Gene Symbol: LOC108432510
3 Cross references
155 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSPNAG00000010971
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSPNAG00000009335
Gene Symbol: MDM2
3 Cross references
282 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSPNAG00000012568
Gene Symbol: MET
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).